CAPPED BONUS PLUSPRO - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 16:20:46 17/05/2024 BST | ||
| 1,061 EUR | -1.00% |
|
| Current month | +0.21% | ||
| 1 month | +3.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 1,061 | -1.00% |
| 16/05/24 | 1,071 | -0.41% |
| 15/05/24 | 1,076 | +0.74% |
| 14/05/24 | 1,068 | +0.05% |
| 13/05/24 | 1,067 | +2.69% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 04:20 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN99J5 |
| ISIN | DE000PN99J58 |
| Date issued | 28/02/2024 |
| Strike | 826.8 kr |
| Maturity | 21/08/2025 (461 Days) |
| Parity | 0.83 : 1 |
| Emission price | 1,000 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,097 € |
|---|---|
| Lowest since issue | 982.5 € |
| Spread | 10 € |
| Spread % | 0.93% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- Certificat
